The effective shelf creates immediate secondary overhang — the company can sell shares into the market at any time. With no minimum offering and a best-efforts agent, shares may be dribbled out over time, creating persistent downward pressure. Traders should watch for a PR announcing any closings or pricing of tranches; any press release referencing 'closing' of this offering would signal imminent dilution and likely send the stock lower. The ACTUARIAL VERDICT on the effect-ipo-context/effect-shelf-context combo is a statistically significant AMPLIFIER (PMI=6.46, q=0.000), meaning cross-filing escalates bearish impact — this is not a routine shelf.
Price Chart
Executive Summary
Envoy Medical's Form S-1 (File No. 333-290927) became effective on June 16, 2026. This allows the company to proceed with its previously disclosed mixed-shelf offering of up to 47,169,811 shares of Class A common stock, pre-funded warrants, and multiple series of warrants at an assumed combined price of $0.53 per unit, representing substantial potential dilution of roughly 2.4x current shares outstanding. The company engages H.C. Wainwright as placement agent on a reasonable best-efforts basis with no minimum offering requirement.
Key Facts
- Form S-1 effective June 16, 2026; shelf registration now live under Rule 415.
- Offering comprises up to 47.17M shares of common stock, plus pre-funded warrants, 28.3M Series A-1 warrants, 47.17M Series A-2 warrants, and 3.3M placement agent warrants.
- Combined assumed offering price of $0.53 per share/warrant unit (slightly below the $0.53 closing price on Feb 5, 2026).
- No minimum offering requirement; offering terminates Feb 28, 2026 unless extended.
- Total shares underlying warrants add up to ~125.9M shares, implying massive dilution relative to current ~$50M market cap.
- Cross-filing S-1/A from Feb 9, 2026 confirms this is an at-the-market continuous offering, not a traditional IPO.
Financial Impact
Potential gross proceeds of ~$25M if all shares and pre-funded warrants are sold at the assumed price; however, dilution from full warrant exercise could bring total shares outstanding to over 170M (current ~20M), representing ~750%+ dilution. Market cap is $50M, so offering size is ~50% of current market cap in primary shares alone, with additional overhang from warrants.
Risk Factors
- Immediate dilution risk — shares can be sold at any time into $0.53-range market price.
- Warrant overhang is enormous (~125M additional shares exercisable), capping any upside rally.
- No minimum offering means the company can sell shares in small tranches, extending pressure over weeks.
- Stock is already at a low absolute price ($0.53), making further dilution particularly punishing to existing holders.
- H.C. Wainwright has strong incentives to execute quickly — their fees depend on closing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002008 |
| Document: 9999999995-26-002008-index.html | 9999999995-26-002008 |
| Document: 9999999995-26-002008.txt | 9999999995-26-002008 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $5.11 | awaiting T+60 | — | $6.51 (−27.40%) |
Oct 7, 2026 20d ago | 8-K | $0.6534 | awaiting T+60 | — | $6.51 (+896.33%) |
Sep 2, 2026 7w ago | DEFA14A | $0.7301 | awaiting T+60 | — | $6.51 (+791.66%) |
Aug 10, 2026 11w ago | 8-K | $0.7700 | awaiting T+60 | — | $6.51 (+745.45%) |
Jun 30, 2026 17w ago | 8-K | $0.7901 $0.7161 | ▼ −9.37% | ▼ −12.24% | $6.51 (+723.95%) |
Jun 17, 2026 19w ago | EFFECT | $0.6544 $0.7402 | ▼ −13.11% | ▼ −9.96% | $6.51 (−894.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers